Skin Affecting Patents (Class 514/18.6)
-
Publication number: 20110306560Abstract: Disclosed herein is a method for reducing the rate of degradation of proteins in an animal, comprising contacting cells of the animal with certain boronic ester and acid compounds. Also disclosed herein are novel boronic ester and acid compounds, their synthesis and uses.Type: ApplicationFiled: August 19, 2011Publication date: December 15, 2011Applicant: Millennium Pharmaceuticals, Inc.Inventors: Julian Adams, Yu-Tung Ma, Ross Stein, Matthew Baevsky, Louis Grenier, Louis Plamondon
-
Publication number: 20110305634Abstract: The present invention provides compositions and methods for treating disorders associated with epithelial tissues.Type: ApplicationFiled: June 10, 2011Publication date: December 15, 2011Applicant: University of Washington through its Center for CommercializationInventors: Andre Lieber, Hongjie Wang
-
Patent number: 8076296Abstract: A topical composition having (i) an isolated polypeptide having the sequence of SEQ ID NO: 1 or a functional equivalent thereof, and (ii) a cosmetically acceptable carrier; and use thereof.Type: GrantFiled: July 28, 2008Date of Patent: December 13, 2011Assignee: Natural Beauty Bio-Technology LimitedInventors: Jidai Chen, Yanping Cong
-
Publication number: 20110301091Abstract: Compositions and methods used to reduce the visible signs of aging of the skin by recalibrating the expression of genes, genetic networks, and cellular pathways in the human skin, particularly using combinations of natural compounds that produce synergistic effects on the expression of genes and genetic networks.Type: ApplicationFiled: November 3, 2009Publication date: December 8, 2011Inventors: Giammaria Giuliani, Raymond Rodriguez, Kevin Dawson
-
Publication number: 20110300199Abstract: Peptides of general formula (I): R1-Wp-Xn-AA1-AA2-AA3-AA4-Ym-R2 their stereoisomers, mixtures thereof, and/or their cosmetically or pharmaceutically acceptable salts, a method of preparation, cosmetic or pharmaceutical compositions containing them and their use for the treatment, prevention and/or care of conditions, disorders and/or diseases of the skin, mucous membranes and/or scalp.Type: ApplicationFiled: February 16, 2010Publication date: December 8, 2011Applicant: LIPOTEC, S.A.Inventors: Nuria Garcia Sanz, Wim Van Den Nest, Cristina Carreno Serraima, Antonio Ferrer Montiel, Juan Cebrian Puche, Nuria Alminana Domenech
-
Publication number: 20110301090Abstract: A wound healing composition comprising an amount of heat shock protein effective to promote wound healing and a method thereof to apply the composition. A preferred heat shock protein is either full-length hsp90? or the middle domain plus the charged sequence of hsp90?. The composition is topically applied to skin wounds, covering the outer surface of the wound. The heat shock protein acts by promoting migration of both human epidermal keratinocyte and dermal fibroblasts to the wound in order to close, heal, and remodel the wound.Type: ApplicationFiled: August 15, 2011Publication date: December 8, 2011Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: WEI LI, MEI CHEN, DAVID T. WOODLEY
-
Publication number: 20110294738Abstract: The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHR1, also known as parathyroid hormone/parathyroid hormone related protein receptor. The PTHR1 compounds are derived from the intracellular loops and domains of the PTHR1 receptor. The invention also relates to the use of these PTHR1 receptor compounds and pharmaceutical compositions comprising the PTHR1 receptor compounds in the treatment of diseases and conditions associated with PTHR1 receptor modulation, such as osteoporosis; humoral hypercalcemia of malignancy; osteolytic and osteoblastic metastasis to bone; primary and secondary hyperparathyroidism associated increase in bone absorption; vascular calcification; psychiatric disorders and cognitive disorders associated with hyperparathyroidism; dermatological disorders; and excess hair growth.Type: ApplicationFiled: November 4, 2009Publication date: December 1, 2011Inventors: Yong Ren, Athan Kuliopulos, Thomas J. McMurry
-
Publication number: 20110293557Abstract: The invention relates to a conjugate that comprises an Apo A molecule or a functionally equivalent variant thereof and a compound of therapeutic interest wherein both components are covalently coupled as well as to the use of said conjugates in therapy for the specific targeting of said compounds to those tissues showing specific binding sites for the ApoA molecule.Type: ApplicationFiled: June 12, 2009Publication date: December 1, 2011Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Jesús Maria Prieto Valtueña, Pedro Berraondo López, Jessica Fioravanti
-
Publication number: 20110293610Abstract: The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.Type: ApplicationFiled: August 12, 2011Publication date: December 1, 2011Applicant: HUMAN GENOME SCIENCES, INC.Inventors: Steven M. RUBEN, Steven C. BARASH, Gil H. CHOI, Tristan VAUGHAN, David HILBERT
-
Publication number: 20110294731Abstract: Preferred embodiments of the invention relate to compositions, including anti-aging cosmeceuticals for topical application, and more particularly, a skin cream, comprising cell culture medium conditioned by cells grown in two-dimensional culture.Type: ApplicationFiled: February 12, 2010Publication date: December 1, 2011Applicant: INVITRX, INC.Inventor: Habib Torfi
-
Publication number: 20110288031Abstract: The present disclosure relates to Birt-Hogg-Dubé syndrome, nucleic acids encoding the BHD gene, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, and methods of treating BHD skin lesions.Type: ApplicationFiled: July 11, 2011Publication date: November 24, 2011Inventors: Laura S. Schmidt, Michelle Warren, Jorge R. Toro, Berton Zbar, Michael L. Nickerson, W. Marston Linehan, Maria L. Turner
-
Publication number: 20110288025Abstract: Provided are a folyl extract of fermented soybean (EFS) produced by fermenting a culture including a folic acid and soybean extract by using a microorganism, and a composition including the folyl EFS. The folyl EFS has an anti-histamine effect, an anti-allergic effect, a calcium-absorption-promotion effect, a bone-growth-promotion effect, a cell growth promotion effect, a collagen biosynthesis promotion effect, a wrinkle improvement effect, and an UV-induced cell damage inhibition effect. Accordingly, the folyl EFS can be used in a skin external application or cosmetic composition, a health supplement food composition, a feed composition, and a pharmaceutical composition.Type: ApplicationFiled: October 2, 2008Publication date: November 24, 2011Applicant: Damy Chemical Co., Ltd.Inventors: Boo Sun Cho, Kwang Nyeon Kim
-
Publication number: 20110287040Abstract: The subject invention pertains to peptides and salts thereof that are useful as anti-inflammatory agents and to compositions containing such peptides and salts as active ingredients. Specifically exemplified herein are endomorphin-1 peptide (EM-1), analogs and salts thereof, and uses for modulation of calcitonin gene-related peptide (CGRP) production and/or substance P (SP) and for treatment of inflammation, particularly neurogenic inflammation.Type: ApplicationFiled: May 23, 2011Publication date: November 24, 2011Inventors: Theodore E. Maione, Joseph Carozza, C. Dean Maglaris
-
Publication number: 20110280876Abstract: A peptide fragment of the netrin-4 protein and nucleic acids coding for the peptide are described. The peptide can inhibit endothelial cell proliferation and cell migration, as well as activate the proliferation and migration of pericytes and smooth muscle cells. Pharmaceutical formulations containing the peptide and/or the nucleic acids can be used to treat a variety of tumoral and non-tumoral pathologies.Type: ApplicationFiled: June 29, 2011Publication date: November 17, 2011Applicants: IVS INSTITUT DES VAISSEAUX ET DU SANG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: JEAN PLOUET, Monica Alemany
-
Publication number: 20110280882Abstract: The present invention relates to a polypeptide, described as a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications, particularly for treating or preventing an autoimmune disorder, an inflammatory disorder or damaged skin in an animal.Type: ApplicationFiled: October 29, 2009Publication date: November 17, 2011Applicant: LEUKOLECT ASInventors: Bernt Th. Walther, Mirushe Miftari
-
Publication number: 20110275562Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.Type: ApplicationFiled: May 6, 2009Publication date: November 10, 2011Inventors: Sefik Alkan, Amir Tamiz, Kelly Marie Kitchens, Malarvizhi Durai, Neil Poloso, Rosa A. Carrasco
-
Publication number: 20110269695Abstract: Peptide compounds of general formula (I) R1-(AA)n-X1-Ser-Thr-Pro-X2-(AA)p-R2 were developed that restore the circadian rhythm and resynchronize the biological clock of skin cells. Cosmetic or pharmaceutical compositions that include at least one peptide of general formula (I) in a cosmetically or dermatologically acceptable medium, and a cosmetic treatment method for restoring the circadian rhythm and resynchronising the biological clock of cells to reduce the dysfunctions caused by jet lag and/or nightshift work and/or to prevent or treat the cutaneous signs of aging were also developed.Type: ApplicationFiled: January 7, 2010Publication date: November 3, 2011Applicant: ISP INVESTMENTSInventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto, Isabelle Imbert
-
Publication number: 20110269694Abstract: The present invention relates to peptide compounds of general formula (I) R1-X1-X2-Ser-Pro-Leu-Gln-X3-X4-R2. The present invention also relates, on the one hand, to a cosmetic or pharmaceutical composition comprising at least one peptide of general formula (I) in a cosmetically or dermatologically acceptable medium, and on the other hand to its use in order to prevent or treat the cutaneous signs of aging and to protect the skin against the harmful effects caused by UV radiation. The invention lastly relates to a cosmetic treatment method for preventing and/or combating cutaneous signs of aging and for protecting the skin against the harmful effects caused by UV radiation.Type: ApplicationFiled: January 7, 2010Publication date: November 3, 2011Applicant: ISP INVESTMENTSInventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto, Isabelle Imbert
-
Publication number: 20110269692Abstract: Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures for biological and/or chemical activity. The modulators of the invention are distinguished in one aspect over previous compounds in that they are orally active, and therefore do not have to be injected into the patient. The compositions and methods are useful for reducing estrogen-dependent and estrogen-independent growth of cells, and treating or preventing cancer, such as breast cancer, brain cancer, head-and-neck cancer, thyroid cancer, lung cancer, colon cancer, ovarian cancer, prostate cancer, cervical cancer, and skin cancer.Type: ApplicationFiled: May 16, 2011Publication date: November 3, 2011Inventors: Thomas T. Andersen, James A. Bennett, Herbert I. Jacobson, Fassil B. Mesfin
-
Publication number: 20110269691Abstract: A method of treating a hypopigmentary condition in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. The hypopigmentary condition can be a result of surgery, trauma or vitiligo. A method of treating a hyperpigmentary condition in a subject comprising administering to the subject an amount of inhibitor of SOX9 activity sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering to the subject an amount of prostaglandin D2 (PGD2) and retinoic acid (RA) sufficient to treat cancer.Type: ApplicationFiled: August 15, 2008Publication date: November 3, 2011Inventors: Vincent J. Hearing, Thierry Passeron
-
Publication number: 20110268679Abstract: Described herein are compositions and methods for preventing and/or treating skin diseases including, but not limited to, psoriasis and atopic dermatitis as well as providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photodamaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin, involving aberrant angiogenesis and hyperplasia employing one or more benzo[c]chromen-6-one derivatives.Type: ApplicationFiled: July 11, 2011Publication date: November 3, 2011Inventor: David SHERRIS
-
Patent number: 8048423Abstract: Methods for treating skin disorders by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a skin disorder.Type: GrantFiled: December 9, 2003Date of Patent: November 1, 2011Assignee: Allergan, Inc.Inventor: Eric R. First
-
Publication number: 20110263508Abstract: Described herein are compositions comprising an alpha-MSH analogue and a transdermal delivery system and methods for inducing melanogenesis and/or preventing UV radiation-induced skin damage in a subject by topical administration of these compositions.Type: ApplicationFiled: October 7, 2005Publication date: October 27, 2011Applicant: Clinuvel Pharmaceuticals LimitedInventors: Michael John Kleinig, Kenneth B. Kirby, Berno I. Pettersson, JR.
-
Publication number: 20110262432Abstract: A mutated protein includes the sequence of wild type netrin 4, represented by SEQ ID NO: 2, wherein at least one amino acid of the amino acids at position (13, 68, 183, 205, 234, 331, 332, 353, 472, 515, 589, 625, 626, 627) and (628) is mutated enabling thus to confer 1 to 15 mutations to the wild type protein, or, truncated protein derived from the mutated protein, wherein the 19 first contiguous, or the 31 first contiguous amino acids at the N-terminus part of the mutated protein are deleted; and/or the mutated protein being deleted of all amino acids located after the amino acid in position (477) or of all amino acids located after the amino acid in position (515).Type: ApplicationFiled: July 16, 2009Publication date: October 27, 2011Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jean Plouet, Isabelle Clarisse Solange Plouet, Claire Charlotte Plouet, Anne Florence Plouet, Laurence Leconte, Esma Lejmi
-
Publication number: 20110263486Abstract: The invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, wherein Y is —NRaRb, —NRc?ONRaRb, —NRcC?SNRaRb, —NRcC?NRdNaRb, heterocycle, —C?ONRaRb, heterocycle, or aryl; n is 0 to 8; m is 0, or 1; r is 0 to 3; t is 0 to 3; X is O or N; Z is CH2, C?O, C?S or a single bond; Z1 is CO—R2, CS—R2, (CH2)t—R2 or the side-chain of a naturally occurring amino acid; Z2 is CO—R2, CS—R2 or (CH2)t—R3 or the side-chain of a naturally occurring amino acid; Z3 is CO—R2, CS—R2 or (CH2)t—R4 or the side-chain of a naturally occurring amino acid; Z4 is H, alkyl, alkoxy, or cycloalkyl; R1, R2, R3, and R4 are independently from each other H, OH, SH, NH2, CN, NO2, alkyl, cycloalkyl, heterocycloalkyl, haloalkyl, alkylthio, haloalkyloxy, hydroxyalkyl, hydroxyalkylamino, alkylamino, alkylaryl, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, alkoxyalkyl, alkoxy, aryloxy, heteroaryl, aryl, or halogen.Type: ApplicationFiled: March 11, 2011Publication date: October 27, 2011Applicant: 4SC AGInventors: Johann LEBAN, Martin KRALIK
-
Publication number: 20110263504Abstract: The present invention provides peptides and peptide analogs that have tissue protective activities while having little or no potentially undesirable hematopoietic effects. The peptides and peptide analogs are useful in preventing and treating a variety of diseases and disorders associated with tissue damage.Type: ApplicationFiled: January 22, 2009Publication date: October 27, 2011Inventors: Anthony Cerami, Michael Brines
-
Patent number: 8044027Abstract: A method of using proteins of the SIRT family or of polypeptide or peptide fragments of SIRT proteins as an active ingredient for slimming, alone or in combination with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical and/or dermatological composition. The invention also includes the use of the peptides for treatment of cellulite and/or used to decrease, eliminate or prevent excess fat beneath the skin.Type: GrantFiled: May 11, 2007Date of Patent: October 25, 2011Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20110258713Abstract: The present inventions are directed to compositions and methods regarding the reprogramming of biological samples (such as cells) without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the tranducible compositions thereof.Type: ApplicationFiled: December 23, 2009Publication date: October 20, 2011Applicant: VIVOSCRIPT, INC.Inventors: Yong Zhu, Shili Wu, Jun Bao
-
Publication number: 20110256130Abstract: Disclosed herein, in certain embodiments, are methods and compositions for treating inflammatory disorders. In some embodiments, the methods comprise co-administering synergistic combinations of modulators of inflammation.Type: ApplicationFiled: December 1, 2009Publication date: October 20, 2011Inventors: Joshua Robert Schultz, Benedikt Vollrath, Court Turner
-
Publication number: 20110245181Abstract: Compositions for the treatment of the skin. The compositions reduce and/or reverse the visible appearance of skin damage. In the preferred embodiment, the composition includes Retinyl Palmitate Polypeptide; Ascorbylmethylsilanol Pectinate; Tocopheryl Polypeptide; Cholecalciferol Polypeptide; and Niacinamide Polypeptide.Type: ApplicationFiled: October 1, 2010Publication date: October 6, 2011Inventor: Simon Erani
-
Publication number: 20110239311Abstract: The present invention relates to agonists/activators of NR2F6 (nuclear orphan receptor receptor Ear2) for the treatment of a disease related to an augmented immune response. Furthermore, pharmaceutical compositions comprising said agonists/activators of NR2F6 and a pharmaceutical carrier are comprised. In a further aspect, the present invention provides for a method for identifying immunosuppressants comprising contacting a cell, tissue or a non-human animal comprising a reporter construct for NR2F6-activation with a candidate molecule, measuring the reporter signal and selecting a candidate molecule which alters the reporter signal. Furthermore, the present invention relates to non-human transgenic animals or cells or tissue derived therefrom useful in the provided methods for identifying immunosuppressants.Type: ApplicationFiled: January 11, 2011Publication date: September 29, 2011Applicant: Medizinische Universitat InnsbruckInventors: Gottfried Baier, Natascha Hermann-Kleiter
-
Publication number: 20110237497Abstract: A composition of a glucocorticoid receptor (GR) ligand, or analog thereof, and a V-ATPase inhibitor, or analog thereof. A method for administering such composition to a cell either to increase glucocorticoid transrepression activity or to increase glucocorticoid transactivation activity in the cell. Also, a method for treating a subject having an inflammatory or auto-immune disease by administering such composition.Type: ApplicationFiled: November 18, 2010Publication date: September 29, 2011Inventors: HUAQIANG ERIC XU, Yong Xu, Yuanzheng He
-
Publication number: 20110236325Abstract: The described invention provides methods and compositions utilizing a NELL1 peptide or nucleic acid encoding a NELL1 peptide for treating or preventing a skin condition. The methods include treating or preventing manifestations of aging in human skin, repairing damage to skin, and preventing skin scarring. Methods are also provided for assaying a test peptide for NELL1 activity.Type: ApplicationFiled: January 21, 2011Publication date: September 29, 2011Applicant: NellOne Therapeutics, Inc.Inventors: Dora P. Mitchell, Cymbeline T. Culiat, Beverly W. Lubit
-
Publication number: 20110236367Abstract: The present invention relates to structural studies of dipeptidyl peptidase I (DPPI) proteins, modified dipeptidyl peptidase I (DPPI) proteins and DPPI co-complexes. Included in the present invention is a crystal of a dipeptidyl peptidase I (DPPI) and corresponding structural information obtained by X-ray crystallography from rat and human DPPI. In addition, this invention relates to methods for using structure co-ordinates of DDPI, mutants hereof and co-complexes, to design compounds that bind to the active site or accessory binding sites of DPPI and to design improved inhibitors of DPPI or homologues of the enzyme.Type: ApplicationFiled: May 20, 2010Publication date: September 29, 2011Applicant: TeleNav, Inc.Inventors: Johan Gotthardt OLSEN, Anders Kadziola, Søren Weis Dahl, Connie Lauritzen, Sine Larsen, John Pedersen, Dusan Turk, Marjetka Podobnik, Igor Stern
-
Publication number: 20110237516Abstract: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing novel plant derived peptides or peptidomimetics useful in stimulating elastogenensis and capillary dilatation. The therapeutic compositions of the present invention that comprise novel plant derived peptides or peptidomimetics may be combined with other therapeutic agents.Type: ApplicationFiled: May 17, 2010Publication date: September 29, 2011Inventors: Felipe JIMENEZ, Thomas F. MITTS, Aleksander HINEK
-
Publication number: 20110230415Abstract: The present invention is related to the use of secretagogue peptides repeatedly administered as part of a pharmaceutical composition that prevent and eradicate the deposition of pathological fibrotic material in parenchymal tissues of internal organs like the liver, lungs, esophagus, small intestine, kidneys, blood vessels, joints, and other systemic forms of cutaneous fibrosis of any etiopathogenesis. Additionally, these peptides prevent and eradicate deposition of amiloid and hyaline materials in any of their correspondent chemical forms and tissue manifestations in the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin, among others. By this way, cellular, tissular and organ dysfunctions generated by these depositions are corrected. The peptides of the present invention are infiltrated or topically applied, contributing to prevent and eradicate keloids and hypertrophic scars in the skin, derived as sequelae of burns and other cutaneous trauma.Type: ApplicationFiled: June 1, 2011Publication date: September 22, 2011Inventors: Jorge Berlanga Acosta, Danay Cibrian Vera, Diana Garcia Del Barco Herrera, Gerardo Enrique Guillén Nieto, José Suarez Alba, Ernesto Lopez Mola, Manuel Selman-Housein Sosa, Mariela Vazquez Castillo
-
Publication number: 20110230417Abstract: The invention provides methods for the treatment of diseases and conditions mediated by increased phosphorylation, such as inflammation and cancer. The invention also provides methods for the inhibition of increased phosphorylation in cells, tissues and organs. The methods utilize a phosphate acceptor compound (PAC). The invention also provides products comprising a PAC.Type: ApplicationFiled: June 2, 2011Publication date: September 22, 2011Inventor: David Bar-Or
-
Publication number: 20110230397Abstract: Peptides and their functionally equivalent derivatives, in salified or non-salified form, with the general formula L1-X1—X2—X3—X4, wherein: L1 is H, or acyl, or any natural or non-natural amino acid, optionally N-acylated, N-alkylated and/or C?-alkylated; X1 and X3, which are equal or different, are any natural or non-natural basic amino acid, optionally N-alkylated and/or C?-alkylated; X2 is any natural or non-natural amino acid, optionally N-alkylated and/or C?-alkylated, with the proviso that it is not glycine and amino acids mono-substituted on the ? carbon atom with a linear or cyclic alkyl group, from 1 to 10 carbon atoms, and amino acids mono-substituted on the ? carbon atom with a linear or cyclic alkyl group containing 4 to 10 carbon atoms, or amino acids mono-substituted on the ? carbon atom with an alkyl group containing 1 to 8 carbon atoms, optionally substituted with a carbamoyl, hydroxyl or aromatic group; X4 is any natural or non-natural hydrophobic amino acid, optionally C?-alkylated and/orType: ApplicationFiled: July 19, 2007Publication date: September 22, 2011Inventors: Maria Vincenza Carriero, Mario De Rosa, Vincenzo Pavone
-
Publication number: 20110217249Abstract: The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans.Type: ApplicationFiled: March 2, 2011Publication date: September 8, 2011Inventor: Frank Dreher
-
Publication number: 20110218143Abstract: The invention generally provides compositions and methods for the repair or regeneration of a tissue or organ in need thereof.Type: ApplicationFiled: November 20, 2008Publication date: September 8, 2011Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATIONInventors: Shalesh Kaushal, Mani Annamalai
-
Publication number: 20110217277Abstract: The invention relates to a drug or a dermatological composition containing an avocado peptide extract for treating and/or preventing pruritus, in particular gravidic pruritus, pruritus sine materia, pruritus in newborns, and pruritus originating from a drug.Type: ApplicationFiled: November 6, 2009Publication date: September 8, 2011Inventors: Philippe Msika, Caroline Baudoin, Stéphanie Bredif
-
Patent number: 8012938Abstract: The present invention relates to the use of proteins of the UCP family, or UCP protein polypeptide or peptide fragments, as an active agent, alone or in association with at least one other active agent, in or for the preparation of a pharmaceutical and/or dermatological and/or cosmetic composition. The invention also relates to any composition containing the aforementioned active ingredient, as well as its use as a slimming agent.Type: GrantFiled: December 23, 2004Date of Patent: September 6, 2011Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20110212157Abstract: The present invention describes systems and methods for treating disorders and/or conditions associated with the dermal level of the skin. Such disorders include acne, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, hair loss, dermal infection, and/or actinic keratosis. Methods generally involve administering nanoemulsions (e.g., nanoparticle compositions) comprising at least one therapeutic agent, such as botulinum toxin. In some embodiments, nanoemulsions are prepared, e.g., by high pressure microfluidization, and comprise a particle size distribution exclusively between 10 nm and 300 nm.Type: ApplicationFiled: June 26, 2009Publication date: September 1, 2011Applicant: ANTERIOS, INC.Inventors: Jonathan Edelson, Timothy Kotyla, Boke Zhang
-
Publication number: 20110212161Abstract: Disclosed are a composition and a method for treating skin disorders, including rosacea, pityriasis rosea, erythema, rhinophyma, and rosacea-associated disorders including pimples, papules, pustules, and telangiectasia.Type: ApplicationFiled: February 4, 2011Publication date: September 1, 2011Applicant: Asan Laboratories Company (Cayman), LimitedInventors: Yih-Lin Chung, Nam-Mew Pui, Wei-Wei Chang
-
Publication number: 20110212162Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.Type: ApplicationFiled: February 10, 2011Publication date: September 1, 2011Inventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
-
Publication number: 20110212890Abstract: Disclosed is a stable metastin derivative having excellent biological activities (e.g., a cancer metastasis inhibiting activity, a cancer proliferation inhibiting activity, a gonadotropin secretion promoting activity, a sex hormone secretion promoting activity). A metastin derivative produced by substituting a constituent amino acid in metastin can be improved in stability in the blood and can have an excellent cancer metastasis inhibiting activity, an excellent cancer proliferation inhibiting activity, an excellent gonadotropin secretion inhibiting activity, an excellent sex hormone secretion inhibiting activity and the like by binding the metastin derivative to polyethylene glycol.Type: ApplicationFiled: July 29, 2009Publication date: September 1, 2011Applicant: Takeda Pharmaceutical Company LimitedInventor: Taiji Asami
-
Publication number: 20110212883Abstract: It is an object to provide a radical scavenger, an active oxygen-scavenging agent and the like, which are highly efficacious clinically and novel, and so as to attain the object, 3,4-dihydroxyphenylalanine derivatives such as N-?-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine (5-S-GAD) or pharmaceutically acceptable salts thereof are contained as an active ingredient.Type: ApplicationFiled: January 7, 2011Publication date: September 1, 2011Applicant: InBiotex inc.Inventors: Shunji NATORI, Kunimiki Ootsu, Hajime Okuyama
-
Publication number: 20110206668Abstract: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer.Type: ApplicationFiled: February 3, 2011Publication date: August 25, 2011Applicant: TRILLIUM THERAPEUTICS INC.Inventors: REGINALD M. GORCZYNSKI, DAVID A. CLARK
-
Publication number: 20110206745Abstract: Methods, formulations and kits are described that allow for the controlled release of octreotide, e.g., octreotide acetate, in a subject.Type: ApplicationFiled: April 29, 2011Publication date: August 25, 2011Inventors: Petr KUZMA, Stefanie Decker, Harry Quandt
-
Publication number: 20110207663Abstract: The invention relates to novel peptide comprising FGF-P and methods of use thereof.Type: ApplicationFiled: June 16, 2009Publication date: August 25, 2011Applicant: University of RochesterInventors: Paul Okunieff, Lurong Zhang